NCT01001260终止不适用
Biosynthesis of PGD2 in Vascular Injury
适应症
干预措施
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 终止
- 入组人数
- 51
- 主要终点
- The increment of PGD2 synthesis reflected by an novel biomarker of urinary PGD2 metabolite.
研究概览
简要总结
To investigate the biosynthesis of PGD2 during percutaneous transluminal coronary angioplasty (PTCA) procedure.
详细描述
A) To determine whether biosynthesis of PGD2 is altered in response to vascular injury in humans
B) Patients will be grouped base on their aspirin using status. Three groups of no aspirin but an alternative anti-platelet medicine, low dose (81 mg) aspirin, high dose 325 mg aspirin will be enrolled.
研究设计
- 研究类型
- Observational
- 观察模型
- Case Only
- 时间视角
- Cross Sectional
入排标准
- 年龄范围
- 18 Years 至 99 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients with existing CAD admitted for elective PTCA:
- •Treated with any dose of aspirin daily for at least 5 days, with special interest in those treated with 81 mg aspirin daily or
- •Treated with an alternative antiplatelet therapy, such as clopidogrel, due to aspirin hypersensitivity or PMDs preference or
- •No aspirin therapy at all
- •Patients presenting to the ER with Acute Coronary Syndrome(ACS)who will have a PTCA
- •Patients with stable angina or positive stress tests scheduled for a cardiac catheterization
排除标准
- •History of unstable diabetes (hgb A1c>8 or FBS> 200)
- •Uncontrolled hypertension (SBP > 180, DBP >100)
- •History of an acute confounding disease as judged on clinical screen that according to the investigator may interfere with interpretation of the study results, or compromise the safety of a potential subject.
- •Patients who have taken NSAIDS or COX-2 inhibitors other than aspirin, for at least 10 days prior to PTCA
研究组 & 干预措施
No Aspirin Treatment
干预措施: No ASA (Drug)
81 mg Aspirin Treatment
干预措施: Low dose ASA (Drug)
325 mg Aspirin
干预措施: 325 mg ASA (Drug)
结局指标
主要结局
The increment of PGD2 synthesis reflected by an novel biomarker of urinary PGD2 metabolite.
时间窗: 18-48 hours - which includes 24 hours before the procedure through 18 hours after the procedure for a continuous urine collection.
次要结局
- Whether aspirin could blunt the increment of PGD2 if there is.(18-48 hours - which includes 24 hours before the procedure through 18 hours after the procedure for a continuous urine collection.)
研究者
相似试验
进行中（未招募）
1 期
Phase II: 68Ga-NODAGA-E[c(RGDyK)]2 Angiogenese PET for imaging angiogenesis in ST-Elevation Myocardial Infarction(STEMI)EUCTR2017-002709-36-DKRigshospitalet, Department of Physiology, Nuclear Medicine and PET50
进行中（未招募）
1 期
Phase II: 68Ga-NODAGA-E[c(RGDyK)]2 Angiogenese PET for imaging angiogenesis in ischaemic heart diseaseIschaemic heart diseaseMedDRA version: 20.0Level: LLTClassification code 10023024Term: Ischaemic heart diseaseSystem Organ Class: 100000011627MedDRA version: 20.0Level: LLTClassification code 10008937Term: Chronic ischemic heart disease, unspecifiedSystem Organ Class: 100000011627MedDRA version: 20.0Level: LLTClassification code 10055218Term: Ischemic heart diseaseSystem Organ Class: 100000011627MedDRA version: 20.0Level: LLTClassification code 10008936Term: Chronic ischaemic heart disease, unspecifiedSystem Organ Class: 100000011627EUCTR2017-002712-14-DKRigshospitalet, Department of Physiology, Nuclear Medicine and PET50
已完成
3 期
Effects of PGI2 Analogue Use on the Development of Chronic Allograft NephropathyChronic Allograft NephropathyNCT01056835Seoul National University Hospital40
撤回
2 期
A Trial Of PF-04856884 In Patients With Recurrent GlioblastomaGlioblastomaNCT01225510Pfizer
已完成
不适用
Regulation of Placental Vascular Reactivity in Pregnancy-induced HypertensionCardiovascular DiseasesHeart DiseasesPregnancy ToxemiasHypertensionNCT00005208National Heart, Lung, and Blood Institute (NHLBI)